While numerous drugs have shown promise in reducing inflammation and related complications in NASH by regulating KC activation (Xin et al., 2021); (Yin et al., 2021), there is still a significant gap between animal experiments and clinical trials. The gene discussed is CALCA; the disease is metabolic dysfunction-associated steatohepatitis.